Antibiotic

Iterum Therapeutics Provides Regulatory Update

Retrieved on: 
Thursday, July 1, 2021

While we are disappointed by this news, we continue to believe in the potential of sulopenemto help address the growing challenge of antibiotic resistance, said Corey Fishman, Chief Executive Officer of Iterum Therapeutics.

Key Points: 
  • While we are disappointed by this news, we continue to believe in the potential of sulopenemto help address the growing challenge of antibiotic resistance, said Corey Fishman, Chief Executive Officer of Iterum Therapeutics.
  • Iterum Therapeutics is advancing its first compound, sulopenem, a novel penem anti-infective compound, in Phase 3 clinical development with an oral formulation and IV formulation.
  • Iterum Therapeutics has received Qualified Infectious Disease Product (QIDP) and Fast Track designations for its oral and IV formulations of sulopenem in seven indications.
  • Except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

Entasis Therapeutics Introduces ETX0462, a First-in-Class Candidate, Targeting Multidrug-Resistant Gram-Negative and Biothreat Pathogens

Retrieved on: 
Thursday, July 1, 2021

ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.

Key Points: 
  • ETX0462 potentially represents the first new antibiotic class in 35 years to treat MDR Gram-negative and biothreat infections.
  • Similar in vivo efficacy was also demonstrated for the biothreat pathogens Y. pestis and B. pseudomallei.
  • Entasis demonstrated that ETX0462 was well tolerated in a rat 14-day GLP toxicology study reaching the limit dose of 2,000 mg/kg.
  • Entasis pathogen-targeted design platform has produced a pipeline of product candidates, including SUL-DUR (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacterales infections) and ETX0462 (targeting Pseudomonas infections).

Use of antibiotics in animals is decreasing

Retrieved on: 
Wednesday, June 30, 2021

The significant fall in antibiotic use in food-producing animals suggests that the measures taken at country level to reduce use are proving to be effective.

Key Points: 
  • The significant fall in antibiotic use in food-producing animals suggests that the measures taken at country level to reduce use are proving to be effective.
  • Use of a class of antibiotics called polymyxins, which includes colistin, nearly halved between 2016 and 2018 in food-producing animals.
  • The report also identifies links between antimicrobial consumption in animals and AMR in bacteria from food-producing animals, which in turn is associated with AMR in bacteria from humans.
  • Experts found an association between resistance in these bacteria in animals and resistance in the same bacteria in humans.

Phico Therapeutics Appoints Richard Nagle as Chairman of its Board

Retrieved on: 
Monday, June 28, 2021

Phico Therapeutics Ltd (Phico), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, today announced the appointment of Richard Nagle as Chair of its Board of Directors.

Key Points: 
  • Phico Therapeutics Ltd (Phico), a biotechnology company developing engineered phage technology as the basis of a new generation of antibiotics to overcome antibacterial resistance, today announced the appointment of Richard Nagle as Chair of its Board of Directors.
  • Richard Nagle is an experienced biotech executive and has built and developed business solutions across the international biopharma sector.
  • Dr. Heather Fairhead, Phico Founder and CEO commented: We are delighted to welcome Richard as Chair of our Board with his wealth of executive and commercial experience.
  • Richard Nagle added: This is an extremely exciting time for Phico Therapeutics, and I am delighted to be joining this dynamic business, which has been at the forefront of building technological solutions to antibacterial resistance.

Recce Pharmaceuticals to Present at World Microbe Forum

Retrieved on: 
Monday, June 21, 2021

SYDNEY, Australia, June 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent abstract in the 2021 program.

Key Points: 
  • SYDNEY, Australia, June 21, 2021 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Ltd (ASX:RCE) (FSE:R9Q) (Company), the Company developing new classes of synthetic anti-infectives, has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent abstract in the 2021 program.
  • The presentation will be in the format of an iposter (digital poster) with a live virtual Q&A session by Michele Dilizia, Chief Scientific Officer of Recce Pharmaceuticals.
  • The session presents expanded details on recently announced data supporting the Companys lead synthetic anti-infective compound, RECCE 327, and its novel, multi-layered mechanism of action (MoA) at the World Microbe Forum being held virtually on June 20-24, 2021.
  • Recces anti-infective pipeline is unique and comprised of broad-spectrum synthetic polymer antibiotics RECCE 327, RECCE 435, and RECCE 529 for viral infections with unique mechanisms of action against hyper-mutation on bacteria and viruses, respectively.

TBD Media Group's New Campaign Gives a Platform to the Leaders at this Pivotal Moment of Business and Society

Retrieved on: 
Thursday, June 17, 2021

LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.

Key Points: 
  • LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.
  • Throughout history there have been pivotal moments that changed society, unlocked new potential, and altered the world as we knew it thereafter.
  • In 1903, the Wright Brothers achieved the first airplane flight, claiming the skies for personal and commercial travel.
  • In 1928, Doctor Alexander Fleming discovered Penicillin, paving the way for research into antibiotics and revolutionising how we use medicine.

TBD Media Group's New Campaign Gives a Platform to the Leaders at this Pivotal Moment of Business and Society

Retrieved on: 
Thursday, June 17, 2021

LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.

Key Points: 
  • LONDON, June 17, 2021 /PRNewswire/ --TBD Media Group announces the launch of a brand-new and ground-shaking new documentary series: 50 Global Leaders.
  • Throughout history there have been pivotal moments that changed society, unlocked new potential, and altered the world as we knew it thereafter.
  • In 1903, the Wright Brothers achieved the first airplane flight, claiming the skies for personal and commercial travel.
  • In 1928, Doctor Alexander Fleming discovered Penicillin, paving the way for research into antibiotics and revolutionising how we use medicine.

Author of Perilous Pills Warns Public About Fluoroquinolone Antibiotic Harm

Retrieved on: 
Wednesday, June 16, 2021

EAST BOOTHBAY, Maine, June 16, 2021 /PRNewswire/ -- Marilyn Beardsley Heise discovered that opioids aren't the only dangerous drugs after she took a commonly-prescribed fluoroquinolone antibiotic called Levaquin and developed severe tendinitis.

Key Points: 
  • EAST BOOTHBAY, Maine, June 16, 2021 /PRNewswire/ -- Marilyn Beardsley Heise discovered that opioids aren't the only dangerous drugs after she took a commonly-prescribed fluoroquinolone antibiotic called Levaquin and developed severe tendinitis.
  • Heise started investigating and discovered hundreds of thousands had been harmed by these drugs, which include Cipro and Avelox.
  • Extensive research resulted in a book called Perilous Pills, Protecting Yourself from Fluoroquinolone Injury .
  • Much more attention and research are needed, according to the author.

Researchers Discover Critical Role of Hydrogen Sulfide in Ability of Bacteria to Survive Antibiotics

Retrieved on: 
Thursday, June 10, 2021

NEW YORK, June 10, 2021 /PRNewswire/ -- The signaling molecule hydrogen sulfide (H2S) plays a critical role in antibiotic tolerance, the innate ability of bacteria to survive normally lethal levels of antibiotics, a new study finds.

Key Points: 
  • NEW YORK, June 10, 2021 /PRNewswire/ -- The signaling molecule hydrogen sulfide (H2S) plays a critical role in antibiotic tolerance, the innate ability of bacteria to survive normally lethal levels of antibiotics, a new study finds.
  • In one defense mechanism, tolerant bacteria, also called "persisters," stop multiplying (proliferating), reducing their energy use (metabolism) to survive antibiotic treatment, but resuming growth when the treatment ends.
  • Persisters are particularly abundant in biofilms, bacterial colonies that live in tough polymeric matrices which further prevent their eradication.
  • "New approaches are urgently neededto preventthis, and our study suggeststhatsuppressing bacterial H2S would make different antibiotics more potent."

Paratek Pharmaceuticals Hosting Investor Webinar with Corporate Updates and Key Opinion Leader and Patient Advocate Presentations on Non-Tuberculous Mycobacteria, M. abscessus

Retrieved on: 
Thursday, June 10, 2021

During the webinar, Paratek will provide a corporate overview and an update on NUZYRA (omadacycline), the companysonce-daily oral and intravenous antibiotic and discuss future development opportunities.

Key Points: 
  • During the webinar, Paratek will provide a corporate overview and an update on NUZYRA (omadacycline), the companysonce-daily oral and intravenous antibiotic and discuss future development opportunities.
  • His Center for Infectious Disease Studies has served as the lead institution and coordinating center for multiple cohort studies and clinical trials.
  • As the public face of the organization, she presents regularly at conferences on a variety of subjects including patient engagement and original patient preference research.
  • Paratek has a collaboration agreement withZaiLab for the development and commercialization of omadacycline in the greaterChinaregion and retains all remaining global rights.